MCID: CNS004
MIFTS: 57

Constipation

Categories: Gastrointestinal diseases

Aliases & Classifications for Constipation

MalaCards integrated aliases for Constipation:

Name: Constipation 12 29 6 43 44 15

Classifications:



External Ids:

Disease Ontology 12 DOID:2089
ICD10 33 K59.0 K59.00
ICD9CM 35 564.0 564.00
MeSH 44 D003248
NCIt 50 C37930
SNOMED-CT 68 14760008
UMLS 73 C0009806

Summaries for Constipation

MedlinePlus : 43 Constipation means that a person has three or fewer bowel movements in a week. The stool can be hard and dry. Sometimes it is painful to pass. At one time or another, almost everyone gets constipated. In most cases, it lasts a short time and is not serious. There are many things you can do to prevent constipation. They include Eating more fruits, vegetables and grains, which are high in fiber Drinking plenty of water and other liquids Getting enough exercise Taking time to have a bowel movement when you need to Using laxatives only if your doctor says you should Asking your doctor if medicines you take may cause constipation It's not important that you have a bowel movement every day. If your bowel habits change, however, check with your doctor. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Constipation is related to hirschsprung disease 1 and intestinal pseudo-obstruction. An important gene associated with Constipation is RET (Ret Proto-Oncogene), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Diltiazem and Acetylcholine have been mentioned in the context of this disorder. Affiliated tissues include colon, testes and lung, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A bowel dysfunction that is characterized by infrequent or difficult evacuation of feces.

Wikipedia : 76 Constipation refers to bowel movements that are infrequent or hard to pass. The stool is often hard and... more...

Related Diseases for Constipation

Diseases related to Constipation via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 313)
# Related Disease Score Top Affiliating Genes
1 hirschsprung disease 1 32.3 EDNRB GDNF RET VIP
2 intestinal pseudo-obstruction 32.2 EDNRB FLNA RET SST
3 hypoganglionosis 32.1 GDNF RET
4 irritable bowel syndrome 32.0 CCK HTR3A HTR4 MLN PYY SLC6A4
5 intestinal obstruction 32.0 EDNRB FLNA GDNF MLN RET
6 central hypoventilation syndrome, congenital 31.5 EDNRB GDNF RET
7 diarrhea 30.8 CCK HTR3A SST
8 megacolon 30.7 EDNRB GDNF RET VIP
9 anismus 30.4 TAC1 VIP
10 gastroesophageal reflux 30.3 CCK MLN PYY VIP
11 carcinoid syndrome 30.2 HTR3A PYY SST
12 dyspepsia 30.1 CCK HTR3A SLC6A4 SST
13 gastroparesis 30.0 CCK HTR3A MLN MLNR
14 functional diarrhea 30.0 HTR3A HTR4 TAC1
15 waardenburg's syndrome 30.0 EDNRB KIT RET
16 colonic pseudo-obstruction 29.9 HTR4 KIT MLN MLNR SST
17 multiple endocrine neoplasia, type iib 29.9 EDNRB GDNF RET
18 gastrointestinal system disease 29.9 CCK HTR4 KIT MLN PYY SST
19 pheochromocytoma 29.7 GDNF RET SST VIP
20 pain agnosia 29.7 CCK OPRM1 TAC1
21 outlet dysfunction constipation 12.3
22 coarse face hypotonia constipation 12.1
23 fecal incontinence 11.4
24 opitz-kaveggia syndrome 11.3
25 pitt-hopkins syndrome 11.3
26 porphyria 11.3
27 parkinson disease, late-onset 11.3
28 sacral defect with anterior meningocele 11.2
29 hemorrhoid 11.2
30 colorectal cancer 11.1
31 celiac disease 1 11.1
32 porphyria, acute hepatic 11.1
33 primary hyperparathyroidism 11.1
34 neurogenic bowel 11.1
35 adrenomyodystrophy 11.1
36 bartter disease 11.1
37 beriberi 11.1
38 intestinal volvulus 11.1
39 disseminated peritoneal leiomyomatosis 11.1
40 ogilvie syndrome 11.1
41 ulcerative proctitis 11.1
42 hashimoto thyroiditis 10.9
43 urofacial syndrome 1 10.9
44 fg syndrome 2 10.9
45 fg syndrome 4 10.9
46 neuropathy, hereditary sensory and autonomic, type vii 10.9
47 adiposis dolorosa 10.8
48 dementia, lewy body 10.8
49 epidermolysis bullosa simplex, dowling-meara type 10.8
50 hyperparathyroidism 2 with jaw tumors 10.8

Graphical network of the top 20 diseases related to Constipation:



Diseases related to Constipation

Symptoms & Phenotypes for Constipation

GenomeRNAi Phenotypes related to Constipation according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.49 FLNA
2 Decreased viability GR00221-A-1 10.49 KIT RET
3 Decreased viability GR00221-A-2 10.49 RET
4 Decreased viability GR00221-A-4 10.49 RET
5 Decreased viability GR00231-A 10.49 RET
6 Decreased viability GR00240-S-1 10.49 SST
7 Decreased viability GR00301-A 10.49 KIT RET
8 Decreased viability GR00381-A-1 10.49 EDNRB HTR3A HTR4 MLN MLNR PPOX
9 Decreased viability GR00381-A-3 10.49 HTR3A MLN SLC6A4
10 Decreased viability GR00402-S-2 10.49 AQP3 CCK CLCN2 EDNRB FLNA GDNF
11 no effect GR00402-S-1 9.62 AQP3 CCK CLCN2 EDNRB FLNA GDNF

MGI Mouse Phenotypes related to Constipation:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.44 AQP3 CCK CLCN2 EDNRB FLNA GDNF
2 homeostasis/metabolism MP:0005376 10.31 AQP3 CCK CLCN2 EDNRB FLNA HTR3A
3 growth/size/body region MP:0005378 10.21 AQP3 EDNRB FLNA GDNF HTR3A HTR4
4 cardiovascular system MP:0005385 10.19 AQP3 CLCN2 EDNRB FLNA GDNF KIT
5 digestive/alimentary MP:0005381 10.18 AQP3 CLCN2 EDNRB FLNA GDNF KIT
6 mortality/aging MP:0010768 10.17 AQP3 EDNRB FLNA GDNF HTR3A HTR4
7 endocrine/exocrine gland MP:0005379 10.16 CCK CLCN2 EDNRB GDNF HTR3A KIT
8 immune system MP:0005387 10.11 AQP3 CLCN2 EDNRB FLNA GDNF HTR3A
9 nervous system MP:0003631 10.1 CCK CLCN2 EDNRB FLNA GDNF HTR3A
10 normal MP:0002873 9.81 FLNA KIT OPRM1 PYY RET SLC6A4
11 renal/urinary system MP:0005367 9.61 AQP3 CCK EDNRB GDNF HTR3A KIT
12 respiratory system MP:0005388 9.23 AQP3 EDNRB FLNA HTR4 KIT NALCN

Drugs & Therapeutics for Constipation

Drugs for Constipation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 819)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diltiazem Approved, Investigational Phase 4,Phase 3,Phase 1 42399-41-7 39186
2
Acetylcholine Approved Phase 4,Phase 2,Phase 3,Not Applicable 51-84-3 187
3
Cyclobenzaprine Approved Phase 4,Not Applicable 303-53-7 2895
4
Amitriptyline Approved Phase 4,Not Applicable 50-48-6 2160
5
Oxybutynin Approved, Investigational Phase 4,Phase 3,Not Applicable 5633-20-5 4634
6
Ferrous fumarate Approved Phase 4,Phase 3,Early Phase 1,Not Applicable 141-01-5
7
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7439-89-6 23925
8
Ropivacaine Approved Phase 4,Phase 3,Phase 2,Not Applicable 84057-95-4 175805 71273
9
Ropinirole Approved, Investigational Phase 4 91374-21-9, 91374-20-8 497540 5095
10
Dopamine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 51-61-6, 62-31-7 681
11
Pramipexole Approved, Investigational Phase 4 104632-26-0 119570 59868
12
Zinc Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7440-66-6
13
Loperamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53179-11-6 3955
14
Bisacodyl Approved Phase 4,Phase 3,Phase 2,Not Applicable 603-50-9
15
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 16590-41-3 5360515
16
Methylnaltrexone Approved Phase 4,Phase 2,Phase 3,Not Applicable 83387-25-1, 916055-93-1 6603824
17
Lactulose Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4618-18-2 11333
18
Naloxone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 465-65-6 5284596
19
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 76-42-6 5284603
20
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
21
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
22
Gabapentin Approved, Investigational Phase 4,Phase 3,Not Applicable 60142-96-3 3446
23
Acetaminophen Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 103-90-2 1983
24
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 437-38-7 3345
25
Dexlansoprazole Approved, Investigational Phase 4,Phase 2,Not Applicable 103577-45-3, 138530-94-6 9578005
26
Lansoprazole Approved, Investigational Phase 4,Phase 2,Not Applicable 103577-45-3 3883
27
Racepinephrine Approved Phase 4,Not Applicable 329-65-7 838
28
Epinephrine Approved, Vet_approved Phase 4,Not Applicable 51-43-4 5816
29
Lidocaine Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 137-58-6 3676
30
Tropisetron Approved, Investigational Phase 4,Not Applicable 89565-68-4, 105826-92-4 5595
31
Magnesium oxide Approved Phase 4,Phase 2,Not Applicable 1309-48-4 14792
32
Lubiprostone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 136790-76-6 656719
33
Naloxegol Approved Phase 4,Phase 3,Phase 2,Phase 1 854601-70-0
34
Magnesium hydroxide Approved, Investigational Phase 4,Phase 2,Not Applicable 1309-42-8
35
Bismuth Subsalicylate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 14882-18-9 53629521
36
Calcium polycarbophil Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 126040-58-2
37
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 148553-50-8 5486971
38
Sorbitol Approved Phase 4,Phase 3 50-70-4 5780
39
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 169590-42-5 2662
40
Ibuprofen Approved Phase 4,Phase 1,Phase 2,Not Applicable 15687-27-1 3672
41
Ondansetron Approved Phase 4,Phase 1,Not Applicable 99614-02-5 4595
42
Hydromorphone Approved, Illicit Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 466-99-9 5284570
43
Octreotide Approved, Investigational Phase 4,Phase 2,Phase 1 83150-76-9 383414 6400441
44
Magnesium citrate Approved Phase 4 3344-18-1
45
Coal tar Approved Phase 4,Phase 3 8007-45-2
46
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 57-27-2 5288826
47
Propranolol Approved, Investigational Phase 4 525-66-6 4946
48
Topiramate Approved Phase 4,Phase 2 97240-79-4 5284627
49
Ketamine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 6740-88-1 3821
50
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943

Interventional clinical trials:

(show top 50) (show all 1629)
# Name Status NCT ID Phase Drugs
1 Lactobacillus Reuteri in Children With Constipation Unknown status NCT01388712 Phase 4
2 Polyethylene Glycol for Childhood Constipation Unknown status NCT01875744 Phase 4 Polyethylene glycol 4000
3 Improving Bowel Habits of Elderly With Probiotics and Non-probiotics Unknown status NCT02949882 Phase 4
4 Effect of Mosapride on Gut Transit in Patients With Chronic Constipation or Constipated Irritable Bowel Syndrome and Healthy Subjects Unknown status NCT02433847 Phase 4 Mosapride
5 Pediatrics Anal Fissures Treatment With Polyethylene Glycol Unknown status NCT02419534 Phase 4 Polyethylene glycol;Polyethylene glycol with Diltiazem
6 Saccharomyces Boulardii in Diarrhea Dominant Irritable Bowel Syndrome Unknown status NCT00543478 Phase 4 Saccharomyces boulardii;Methyl cellulose powder (low viscosity)
7 A Trial Comparing Bowel Preparation and Patient Tolerability of Miralax Versus Golytely Unknown status NCT00889655 Phase 4 Golytely (polyethylene glycol);MiraLax (polyethylene glycol 3350)
8 The Use of Botox in Advanced Parkinson's Patients Experiencing Pain Unknown status NCT02472210 Phase 4 Botulinum Toxin
9 Prucalopride Prior to Small Bowel Capsule Endoscopy Unknown status NCT02806206 Phase 4 Prucalopride;Placebo
10 Postoperative Pain After Intravenous Vitamin C Injection for Arthroscopic Rotator Cuff Repair Unknown status NCT02992028 Phase 4 Intravenous Nutrition (Vitamins) injection;Intravenous Saline injection
11 Manipulation of Visceral Sensitivity and Immune System in IBS Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
12 Cyclobenzaprine Extended Release (ER) for Fibromyalgia Unknown status NCT01041495 Phase 4 cyclobenzaprine ER (AMRIX);placebo
13 Effect of Botulinum Toxin in Neurogenic Bladders in Children With Myelomeningocele Unknown status NCT00175123 Phase 4 Botulinum A toxin
14 The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome (IBS) Unknown status NCT01779765 Phase 4
15 The Use of Iron Therapy for Patients With Anemia After Surgery Unknown status NCT01975272 Phase 4 Ferinject;Ferrous fumarate;Placebo for ferrous fumarate;Placebo for ferinject
16 A Prospective Evaluation of the Strattice-LIFT to Treat Anal Fistula Unknown status NCT02423330 Phase 4
17 Transversus Abdominis Plane Blocks With Abdominoplasty Unknown status NCT01278264 Phase 4 Ropivacaine 0.25%, 0.5 ml/kg;Ropivacaine 0.25%, 0.5 ml/kg
18 Clinical Efficacy of Changing the InterStim® Parameters in Patients With Interstitial Cystitis/Painful Bladder Syndrome Unknown status NCT01312259 Phase 4
19 Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID) Unknown status NCT01515774 Phase 4 Mirapex ER
20 Probiotics in Newly Recognized Type 1 Diabetes Unknown status NCT03032354 Phase 4 Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12
21 Pain Relief In Irritable Bowel Syndrome Unknown status NCT02573844 Phase 4 Proklama
22 The Therapeutic Effects of Insulin and Berberine on Stress Hyperglycemia Unknown status NCT02806999 Phase 4 Berberine; Insulin;Insulin
23 Anti-peristaltic Ileo-sigmoid Anastomosis for the Treatment of Slow-transit Constipation:Therapeutic Evaluation Completed NCT02147574 Phase 4
24 The Effect of Probiotics on Constipation, and Intestinal Microflora in Children With Functional Constipation Completed NCT03054805 Phase 4 Magnesium Oxide;MIYAIRI-BM
25 Lubiprostone in Patients With Multiple Sclerosis Associated Constipation Completed NCT01236534 Phase 4 Lubiprostone;Placebo
26 To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation Completed NCT03060512 Phase 4 Polyethylene Glycol 3350;Movantik
27 Comparison of Lubiprostone and Placebo for the Relief of Constipation From Constipating Medications Completed NCT01096290 Phase 4 lubiprostone;Matched placebo
28 Methylnaltrexone Use for Opioid-induced Postoperative Constipation Completed NCT01773096 Phase 4 Methylnaltrexone;Senna, docusate sodium, bisacodyl, magnesium hydroxide, Miralax
29 Evaluation of Long-term Prucalopride Treatment With Chronic Constipation in Subjects Aged ≥ 18 Years Completed NCT01424228 Phase 4 placebo;prucalopride
30 Soy Polysaccharide Fiber for the Treatment of Chronic Constipation in Children: a Randomized, Double-blind Trial Completed NCT01267370 Phase 4
31 Lactobacillus Reuteri DSM 17938 in Functional Constipation Completed NCT01244945 Phase 4
32 Efficacy and Safety of Prucalopride in Combination With Polyethylene Glycol or Lactulose in Women With Chronic Constipation Completed NCT02228616 Phase 4 Prucalopride;Polyethylene glycol (PEG);Lactulose
33 Efficacy and Tolerability of PEG-only Laxative for Fecal Impaction and Chronic Constipation in Children Completed NCT01592734 Phase 4 Polyethylene glycol with electrolytes
34 Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness Completed NCT00672477 Phase 4 Methylnaltrexone;Placebo
35 The Efficacy of Mutaflor(E. Coli Nissle 1917, Mutaflor®) for Chronic Constipation:Multicenter Study Completed NCT02726295 Phase 4 E. coli Nissle 1917(Mutaflor®);Placebo
36 Polyethyleneglycol3350 vs Tegaserod in Treatment of Patients With Chronic Constipation Completed NCT00153140 Phase 4 polyethyleneglycol3350
37 Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness Completed NCT00672139 Phase 4 Methylnaltrexone bromide
38 An Open-Label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation Completed NCT02590432 Phase 4 Linaclotide 290 micrograms;Linaclotide 145 micrograms;Linaclotide 72 micrograms
39 Comparison of PEG Solutions With and Without Electrolytes in the Treatment of Constipation Completed NCT00603681 Phase 4 Polyethylene glycol 4000;Polyethylene glycol 4000 with electrolytes
40 Lcr35 for Children With Functional Constipation Completed NCT01985867 Phase 4
41 The Effectiveness of Lubiprostone in Constipated Diabetics Completed NCT01170039 Phase 4 Lubiprostone;Placebo
42 Preference of Tegaserod vs. PEG 3350 in Patients With Constipation Completed NCT00171522 Phase 4 Tegaserod and Polyethylene Glycol 3350
43 Dietary Fiber Mixture in Constipated Pediatric Patients Completed NCT01333787 Phase 4
44 Safety and Efficacy of Lubiprostone in Pediatric Patients With Constipation Completed NCT00452335 Phase 4 Lubiprostone;Lubiprostone;Lubiprostone
45 Efficacy, Safety and Tolerability of Tegaserod in Patients With Chronic Constipation Completed NCT00149877 Phase 4 Tegaserod
46 A Single-arm, Study to Assess the Effect and Tolerability of Standardised Laxative Therapy (SLT) for the Reversal of Opioid-induced Constipation (OIC). Completed NCT01957046 Phase 4 Laxative
47 Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation) Completed NCT02839889 Phase 4 Naloxegol;Placebo
48 Comparison of PolyethyleneGlycol and Placebo for Relief of Constipation From Constipating Medications Completed NCT00153127 Phase 4 polyethyleneglycol3350
49 A Pilot Study of a New MiraLax® Dose Formulation For Use in Constipated Children Completed NCT00319670 Phase 4 MiraLax
50 Study Comparing PEG 3350 Laxative to Placebo in the Treatment of Occasional Constipation (Study CL2007-12)(P08216) Completed NCT00770432 Phase 4 Polyethylene glycol 3350

Search NIH Clinical Center for Constipation

Cochrane evidence based reviews: constipation

Genetic Tests for Constipation

Genetic tests related to Constipation:

# Genetic test Affiliating Genes
1 Constipation 29

Anatomical Context for Constipation

MalaCards organs/tissues related to Constipation:

41
Colon, Testes, Lung, Breast, Brain, Spinal Cord, Kidney

Publications for Constipation

Articles related to Constipation:

(show top 50) (show all 1821)
# Title Authors Year
1
Spicatoside A in red Liriope platyphylla displays a laxative effect in a constipation rat model via regulating mAChRs and ER stress signaling. ( 30387811 )
2019
2
Audit of the diagnosis of rectal evacuation disorders in chronic constipation. ( 30426597 )
2019
3
Effects of a probiotic (SLAB51a8c) on clinical and histologic variables and microbiota of cats with chronic constipation/megacolon: a pilot study. ( 29065705 )
2018
4
Dyssynergic defecation: The not so hidden partner in constipation. ( 29971688 )
2018
5
Stepped-wedge randomised trial of laparoscopic ventral mesh rectopexy in adults with chronic constipation: study protocol for a randomized controlled trial. ( 29402303 )
2018
6
Assessment and management of constipation for patients receiving palliative care in specialist palliative care settings: A systematic review of the literature. ( 29431016 )
2018
7
Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: a randomised controlled trial. ( 29959787 )
2018
8
Efficacy and Safety of Subcutaneous Neostigmine for Ileus, Acute Colonic Pseudo-obstruction, or Refractory Constipation. ( 29359574 )
2018
9
Methylnaltrexone bromide for the treatment of opioid-induced constipation. ( 29979903 )
2018
10
Paediatric<i>Clostridium difficile</i>pseudomembranous colitis: a complication of refractory constipation? ( 29444797 )
2018
11
Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic non-cancer pain: a randomized, double-blind, placebo-controlled phase 3 study. ( 29419653 )
2018
12
Erratum: Analysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain [Corrigendum]. ( 29950887 )
2018
13
Abdominal radiograph usage trends in the setting of constipation: a 10-year experience. ( 29392367 )
2018
14
Polyethylene glycol maintenance treatment for childhood functional constipation: A Randomized, Placebo-Controlled Trial. ( 29952829 )
2018
15
Infant Feeding Practices and the Effect in Reducing Functional Constipation Six Years Later: A Randomised Field Trial. ( 29927865 )
2018
16
Plecanatide: a new guanylate cyclase agonist for the treatment of chronic idiopathic constipation. ( 29942351 )
2018
17
Quercetin promotes gastrointestinal motility and mucin secretion in loperamide-induced constipation of SD rats through regulation of the mAChRs downstream signal. ( 29952685 )
2018
18
Long-term outcomes of a Malone antegrade continence enema (MACE) for the treatment of fecal incontinence or constipation in adults. ( 29934702 )
2018
19
Assessing the efficacy of peripherally acting A/-opioid receptor antagonists (PAMORAs) in the treatment of opioid-induced constipation: authors reply. ( 29980606 )
2018
20
Efficacy of Lubiprostone for the Treatment of Opioid-Induced Constipation, Analyzed by Opioid Class. ( 29897589 )
2018
21
Spotlight on naldemedine in the treatment of opioid-induced constipation in adult patients with chronic noncancer pain: design, development, and place in therapy. ( 29391826 )
2018
22
Randomized phase 3 and extension studies: Efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. ( 29912271 )
2018
23
Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Irritable Bowel Syndrome with Constipation (BURDEN IBS-C) Study: Results of an Online Questionnaire. ( 29946799 )
2018
24
Prolonged-release oxycodone/naloxone reduces opioid-induced constipation and improves quality of life in laxative-refractory patients: results of an observational study. ( 29416370 )
2018
25
The Burden of Opioid-Induced Constipation in Younger Patients with Chronic Noncancer Pain. ( 29420795 )
2018
26
Management of Childhood Functional Constipation: Consensus Practice Guidelines of Indian Society of Pediatric Gastroenterology, Hepatology and Nutrition and Pediatric Gastroenterology Chapter of Indian Academy of Pediatrics. ( 29941697 )
2018
27
Effects of Noninvasive Skin Stimulation with Microcones on Constipation: A Double-Blinded Controlled Study. ( 29410718 )
2018
28
Treatment of poststroke constipation with moxibustion: A case report. ( 29901642 )
2018
29
Acupuncture for patients with chronic functional constipation: A randomized controlled trial. ( 29392784 )
2018
30
Are Senna based laxatives safe when used as long term treatment for constipation in children? ( 29429768 )
2018
31
The authors respond: The ED diagnostic workup of constipation in children. ( 29395764 )
2018
32
Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer. ( 29406801 )
2018
33
Current treatment paradigm and landscape for the management of chronic idiopathic constipation in adults: Focus on plecanatide. ( 29979299 )
2018
34
Aetiological spectrum, clinical differentiation and efficacy of polyethylene glycol over lactulose in children with constipation: Experience of 316 cases. ( 29943871 )
2018
35
Clinical practice guidelines from the French National Society of Coloproctology in treating chronic constipation. ( 29406436 )
2018
36
Long-term follow-up of the effects of fecal microbiota transplantation in combination with soluble dietary fiber as a therapeutic regimen in slow transit constipation. ( 29441452 )
2018
37
The effect of fecal microbiota transplantation on psychiatric symptoms among patients with irritable bowel syndrome, functional diarrhea and functional constipation: An open-label observational study. ( 29684865 )
2018
38
Constipation in children: NICE guidance in practice in two emergency departments. ( 29395754 )
2018
39
Multisystem amyloidosis as the unifying diagnosis for constipation, collapse and cardiomyopathy. ( 29991549 )
2018
40
Constipation Burden in Children with Autism Spectrum Disorder: Emergency Department and Healthcare Use. ( 30025674 )
2018
41
Constipation in Children with Autism Spectrum Disorder Associated with Increased Emergency Department Visits and Inpatient Admissions. ( 29866597 )
2018
42
Visceral and Neural Manipulation in Children with Cerebral Palsy and Chronic Constipation: Five Case Reports. ( 30528865 )
2018
43
Constipation and fecal incontinence in children with cerebral palsy. Overview of literature and flowchart for a stepwise approach. ( 30350531 )
2018
44
Characterization of ulcerative colitis-associated constipation syndrome (proximal constipation). ( 30483593 )
2018
45
Microscopic colitis: Diarrhoea or constipation. ( 30323375 )
2018
46
Constipation-Associated Stercoral Colitis. ( 30180104 )
2018
47
Refractory functional constipation: clinical management or appendicostomy? ( 30352206 )
2018
48
Proctalgia and constipation secondary to hypertrophic polyglucosan inclusion body myopathy of the internal anal sphincter: a case report. ( 30352617 )
2018
49
High-dose linaclotide is effective and safe in patients with chronic constipation: A phase III randomized, double-blind, placebo-controlled study with a long-term open-label extension study in Japan. ( 30353619 )
2018
50
Linaclotide increases cecal pH, accelerates colonic transit, and increases colonic motility in irritable bowel syndrome with constipation. ( 30353623 )
2018

Variations for Constipation

ClinVar genetic disease variations for Constipation:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 RET NM_020975.4(RET): c.2753T> C (p.Met918Thr) single nucleotide variant Pathogenic rs74799832 GRCh37 Chromosome 10, 43617416: 43617416
2 RET NM_020975.4(RET): c.2753T> C (p.Met918Thr) single nucleotide variant Pathogenic rs74799832 GRCh38 Chromosome 10, 43121968: 43121968
3 MT-TP; MT-TT m.15923A> G single nucleotide variant Uncertain significance rs193303001 GRCh38 Chromosome MT, 15923: 15923
4 MT-TP; MT-TT m.15923A> G single nucleotide variant Uncertain significance rs193303001 GRCh37 Chromosome MT, 15923: 15923
5 ARID1B NM_020732.3(ARID1B): c.4110G> A (p.Pro1370=) single nucleotide variant Conflicting interpretations of pathogenicity rs797045277 GRCh37 Chromosome 6, 157520041: 157520041
6 ARID1B NM_020732.3(ARID1B): c.4110G> A (p.Pro1370=) single nucleotide variant Conflicting interpretations of pathogenicity rs797045277 GRCh38 Chromosome 6, 157198907: 157198907
7 PPOX NM_000309.4(PPOX): c.1353T> G (p.Tyr451Ter) single nucleotide variant Pathogenic rs148292941 GRCh37 Chromosome 1, 161140885: 161140885
8 PPOX NM_000309.4(PPOX): c.1353T> G (p.Tyr451Ter) single nucleotide variant Pathogenic rs148292941 GRCh38 Chromosome 1, 161171095: 161171095

Expression for Constipation

Search GEO for disease gene expression data for Constipation.

Pathways for Constipation

GO Terms for Constipation

Cellular components related to Constipation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 9.71 EDNRB OPRM1 RET SLC6A4
2 axon GO:0030424 9.65 CCK HTR3A OPRM1 RET TAC1
3 perikaryon GO:0043204 9.61 CCK OPRM1 VIP
4 integral component of plasma membrane GO:0005887 9.56 CLCN2 EDNRB HTR3A HTR4 KIT OPRM1
5 integral component of presynaptic membrane GO:0099056 9.54 HTR3A OPRM1 SLC6A4
6 integral component of postsynaptic membrane GO:0099055 9.33 HTR3A OPRM1 SLC6A4
7 neuronal cell body GO:0043025 9.1 CCK FLNA HTR3A RET SST TAC1
8 plasma membrane GO:0005886 10.13 AQP3 CLCN2 EDNRB FLNA HTR3A HTR4

Biological processes related to Constipation according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.95 CCK EDNRB GDNF KIT VIP
2 response to drug GO:0042493 9.88 PPOX RET SLC6A4 SST
3 negative regulation of apoptotic process GO:0043066 9.88 EDNRB FLNA GDNF KIT RET VIP
4 chemical synaptic transmission GO:0007268 9.81 HTR3A HTR4 SST TAC1
5 regulation of signaling receptor activity GO:0010469 9.8 CCK GDNF MLN PYY SST VIP
6 neuropeptide signaling pathway GO:0007218 9.73 OPRM1 PYY TAC1
7 sensory perception of pain GO:0019233 9.67 EDNRB OPRM1 TAC1
8 neural crest cell migration GO:0001755 9.63 EDNRB GDNF RET
9 mRNA stabilization GO:0048255 9.6 GDNF VIP
10 melanocyte differentiation GO:0030318 9.59 EDNRB KIT
11 negative regulation of adenylate cyclase activity GO:0007194 9.58 EDNRB OPRM1
12 vasoconstriction GO:0042310 9.57 EDNRB SLC6A4
13 positive regulation of renal sodium excretion GO:0035815 9.54 EDNRB TAC1
14 developmental pigmentation GO:0048066 9.52 EDNRB KIT
15 positive regulation of penile erection GO:0060406 9.48 EDNRB VIP
16 response to pain GO:0048265 9.43 EDNRB RET TAC1
17 posterior midgut development GO:0007497 9.37 EDNRB RET
18 enteric nervous system development GO:0048484 9.33 EDNRB GDNF RET
19 G protein-coupled receptor signaling pathway GO:0007186 9.32 CCK EDNRB HTR4 MLN MLNR OPRM1
20 regulation of sensory perception of pain GO:0051930 9.26 CCK EDNRB OPRM1 VIP
21 signal transduction GO:0007165 10.09 CCK EDNRB GDNF HTR3A HTR4 KIT

Molecular functions related to Constipation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.5 GDNF KIT RET
2 peptide hormone receptor binding GO:0051428 9.26 CCK VIP
3 serotonin binding GO:0051378 9.16 HTR3A SLC6A4
4 neuropeptide hormone activity GO:0005184 9.13 CCK PYY VIP
5 hormone activity GO:0005179 9.02 CCK MLN PYY SST VIP

Sources for Constipation

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....